Galit Livnat

1.0k total citations
50 papers, 559 citations indexed

About

Galit Livnat is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Surgery. According to data from OpenAlex, Galit Livnat has authored 50 papers receiving a total of 559 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pulmonary and Respiratory Medicine, 15 papers in Physiology and 5 papers in Surgery. Recurrent topics in Galit Livnat's work include Cystic Fibrosis Research Advances (24 papers), Asthma and respiratory diseases (13 papers) and Respiratory and Cough-Related Research (11 papers). Galit Livnat is often cited by papers focused on Cystic Fibrosis Research Advances (24 papers), Asthma and respiratory diseases (13 papers) and Respiratory and Cough-Related Research (11 papers). Galit Livnat collaborates with scholars based in Israel, United Kingdom and United States. Galit Livnat's co-authors include Lea Bentur, Fahed Hakim, Ronen Bar‐Yoseph, Daphna Vilozni, Eitan Kerem, Michal Gur, Aviv Goldbart, Michal Shteinberg, Rafael M. Nagler and H Abramovici and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Galit Livnat

47 papers receiving 547 citations

Peers

Galit Livnat
Ioanna Loukou Greece
Marina Attanasi Italy
Yvonne Belessis Australia
Metin Aydoğan Türkiye
Henryk Mazurek Poland
Kristina Rueter Australia
Laura Tenero Italy
Francisco Espíldora Spain
Lambang Arianto Denmark
Henrik Wegener Hallas Denmark
Ioanna Loukou Greece
Galit Livnat
Citations per year, relative to Galit Livnat Galit Livnat (= 1×) peers Ioanna Loukou

Countries citing papers authored by Galit Livnat

Since Specialization
Citations

This map shows the geographic impact of Galit Livnat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Galit Livnat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Galit Livnat more than expected).

Fields of papers citing papers by Galit Livnat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Galit Livnat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Galit Livnat. The network helps show where Galit Livnat may publish in the future.

Co-authorship network of co-authors of Galit Livnat

This figure shows the co-authorship network connecting the top 25 collaborators of Galit Livnat. A scholar is included among the top collaborators of Galit Livnat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Galit Livnat. Galit Livnat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shteinberg, Michal, Inbal Golan‐Tripto, Galit Livnat, et al.. (2024). Treatment effects of elexacaftor/tezacaftor/ivacaftor on people with cystic fibrosis heterozygous for 3849+10kbC->T and a class I variant. Journal of Cystic Fibrosis. 24(3). 548–551.
2.
Aviram, Micha, Meir Mei‐Zahav, Dario Prais, et al.. (2023). Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study. Journal of Cystic Fibrosis. 23(1). 41–49. 25 indexed citations
3.
Dagan, Adi, et al.. (2023). P052 Efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with normal/near normal FEV1 (≥70%). Journal of Cystic Fibrosis. 22. S79–S79. 1 indexed citations
4.
Livnat, Galit, et al.. (2022). Pneumonia in the presentation of Kawasaki disease: The syndrome or a sequence of two diseases?. SHILAP Revista de lepidopterología. 10(12). e6676–e6676. 3 indexed citations
5.
Livnat, Galit, Adi Dagan, Einat Shmueli, et al.. (2022). Treatment effects of Elexacaftor/Tezacaftor/Ivacaftor in people with CF carrying non-F508del mutations. Journal of Cystic Fibrosis. 22(3). 450–455. 7 indexed citations
6.
Koren, Ilana, et al.. (2022). Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients. BMC Pharmacology and Toxicology. 23(1). 80–80. 5 indexed citations
7.
8.
Livnat, Galit, et al.. (2021). Improvement in BMI z-score following adenotonsillectomy in adolescents aged 12–18 years: a retrospective cohort study. BMC Pediatrics. 21(1). 184–184. 7 indexed citations
9.
10.
Bar‐Yoseph, Ronen, Anat Ilivitzki, Dan M. Cooper, et al.. (2019). Exercise capacity in patients with cystic fibrosis vs. non-cystic fibrosis bronchiectasis. PLoS ONE. 14(6). e0217491–e0217491. 15 indexed citations
11.
Dagan, Adi, Malena Cohen‐Cymberknoh, Michal Shteinberg, et al.. (2017). Ivacaftor for the p.Ser549Arg (S549R) gating mutation – The Israeli experience. Respiratory Medicine. 131. 225–228. 21 indexed citations
12.
Vilozni, Daphna, et al.. (2016). Assessment of Airway Bronchodilation by Spirometry Compared to Airway Obstruction in Young Children with Asthma. Canadian Respiratory Journal. 2016. 1–6. 9 indexed citations
13.
Shteinberg, Michal, Michael Wilschanski, Aurélie Hatton, et al.. (2016). Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor. Journal of Cystic Fibrosis. 16(1). 45–48. 14 indexed citations
14.
Mei‐Zahav, Meir, Galit Livnat, Lea Bentur, et al.. (2015). The Spectrum of Nocardia Lung Disease in Cystic Fibrosis. The Pediatric Infectious Disease Journal. 34(8). 909–911. 7 indexed citations
15.
Breuer, Oded, et al.. (2015). CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation. Journal of Cystic Fibrosis. 15(3). e25–e27. 50 indexed citations
16.
17.
Livnat, Galit & Lea Bentur. (2009). Non-cystic fibrosis bronchiectasis: review and recent advances. F1000 Medicine Reports. 1. 4 indexed citations
18.
Vilozni, Daphna, et al.. (2009). The potential use of spirometry during methacholine challenge test in young children with respiratory symptoms. Pediatric Pulmonology. 44(7). 720–727. 5 indexed citations
19.
Vilozni, Daphna, et al.. (2009). FRC measurements using body plethysmography in young children. Pediatric Pulmonology. 44(9). 885–891. 8 indexed citations
20.
Hakim, Fahed, et al.. (2007). The Effect of Montelukast on Bronchial Hyperreactivity in Preschool Children. CHEST Journal. 131(1). 180–186. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ioanna Loukou Breakdown of academic impact, for papers by Marina Attanasi Breakdown of academic impact, for papers by Yvonne Belessis Breakdown of academic impact, for papers by Metin Aydoğan Breakdown of academic impact, for papers by Henryk Mazurek Breakdown of academic impact, for papers by Kristina Rueter Breakdown of academic impact, for papers by Laura Tenero Breakdown of academic impact, for papers by Francisco Espíldora Breakdown of academic impact, for papers by Lambang Arianto Breakdown of academic impact, for papers by Henrik Wegener Hallas
Rankless by CCL
2026